Cytokinetics traded at $44.14 this Wednesday July 6th, increasing $0.24 or 0.55 percent since the previous trading session. Looking back, over the last four weeks, Cytokinetics gained 6.39 percent. Over the last 12 months, its price rose by 123.27 percent. Looking ahead, we forecast Cytokinetics to be priced at 39.89 by the end of this quarter and at 36.73 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,167.00 342.00 5.87% -41.24%
Arca Biopharma 2.51 0 0% -32.89%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
Acorda Therapeutics 0.45 -0.04 -7.31% -89.61%
Amgen 245.25 -1.48 -0.60% 0.83%
Bayer 56.19 0.67 1.21% 10.24%
Brainstorm Cell Therapeutics 2.66 -0.04 -1.48% -23.34%
Biogen 215.98 3.40 1.60% -39.22%
Bristol-Myers Squibb 76.22 0.26 0.34% 13.52%
Capricor Therapeutics 3.61 -0.12 -3.22% -27.22%
Cytokinetics 44.14 0.24 0.55% 123.27%
Exelixis 21.53 -0.74 -3.32% 19.81%
Geron 1.86 0.05 2.76% 37.78%
Genocea Biosciences 0.02 0 0% -99.22%
Halozyme Therapeutics 46.75 0.42 0.91% 2.48%
Ionis Pharmaceuticals 36.81 -1.04 -2.75% -5.52%
Intra Cellular Therapies 56.17 -0.92 -1.61% 37.00%
Ligand Pharmaceuticals 95.83 0.40 0.42% -25.68%
Eli Lilly 330.15 2.97 0.91% 40.00%
Merck & Co 93.13 0.49 0.53% 18.55%
Novartis 81.22 0.31 0.38% -4.41%
Pfizer 52.75 1.11 2.15% 34.05%
Regeneron Pharmaceuticals 594.90 -1.66 -0.28% 1.54%
Roche Holding 323.35 4.35 1.36% -9.16%
Sanofi 97.90 0.78 0.80% 12.79%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%

Cytokinetics
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.